Trial Profile
Randomized Phase III Trial of Irinotecan plus Cisplatin vs. bi-weekly Irinotecan after S-1 failure for Patients with Advanced and Recurrent Gastric Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 26 Jan 2013 The overall survival data is being analysed now according to the abstract presented at the 2013 Gastrointestinal Cancers Symposium.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
- 18 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.